rs145397619
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM5PP3
The NM_015046.7(SETX):c.7139G>A(p.Arg2380Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000186 in 1,613,868 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R2380G) has been classified as Pathogenic.
Frequency
Consequence
NM_015046.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SETX | NM_015046.7 | c.7139G>A | p.Arg2380Gln | missense_variant | 24/26 | ENST00000224140.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SETX | ENST00000224140.6 | c.7139G>A | p.Arg2380Gln | missense_variant | 24/26 | 1 | NM_015046.7 | P1 | |
SETX | ENST00000436441.5 | c.1865G>A | p.Arg622Gln | missense_variant | 14/17 | 5 | |||
SETX | ENST00000477049.1 | n.166G>A | non_coding_transcript_exon_variant | 2/5 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152060Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251468Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135906
GnomAD4 exome AF: 0.0000192 AC: 28AN: 1461808Hom.: 0 Cov.: 31 AF XY: 0.0000220 AC XY: 16AN XY: 727200
GnomAD4 genome AF: 0.0000132 AC: 2AN: 152060Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74270
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:2
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2024 | SETX: PM2, PM3, PM5 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 01, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Aug 08, 2019 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jun 16, 2021 | DNA sequence analysis of the SETX gene demonstrated a sequence change c.7139G>A, in exon 24 that results in an amino acid change, p.Arg2380Gln. This sequence change has been described in three non-Finnish European individuals only in the gnomAD population database (dbSNP rs145397619). This sequence change has been previously described in an individual with ataxia with oculomotor apraxia type 2 (AOA2) however a second variant was not identified (PMID: 19696032). Two other changes affecting the same amino acid residue (p.Arg2380Gly, p.Arg2380Trp) have been reported in the homozygous state in individuals with AOA2 (PMIDs: 19696032, 23111195). The p.Arg2380Gln change affects a highly conserved amino acid residue located in the helicase of the SETX protein and in a region where other pathogenic missense variants have been described. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Arg2380Gln substitution. Due to the lack of functional studies, the clinical significance of the p.Arg2380Gln change remains unknown at this time. - |
Amyotrophic lateral sclerosis type 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Feb 08, 2023 | - - |
SETX-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 29, 2023 | The SETX c.7139G>A variant is predicted to result in the amino acid substitution p.Arg2380Gln. This variant was reported along with a SETX nonsense variant in two individuals from a family with spinocerebellar ataxia with axonal neuropathy (Family ATX-27, Baviera-Muñoz et al. 2022. PubMed ID: 36530930). This variant was also reported in the heterozygous state in an individual with spinocerebellar ataxia with axonal neuropathy; however, a second plausible causative variant was not identified (Anheim et al. 2009. PubMed ID: 19696032). This variant is reported in 0.0023% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Different nucleotide substitutions affecting the same amino acid (p.Arg2380Gly and p.Arg2380Trp) have been reported in the homozygous state in individuals with spinocerebellar ataxia with axonal neuropathy (Anheim et al. 2009. PubMed ID: 19696032; Hammer et al. 2012. PubMed ID: 23111195). At this time, the clinical significance of the c.7139G>A (p.Arg2380Gln) variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Feb 08, 2023 | - - |
Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2;C1865409:Amyotrophic lateral sclerosis type 4 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at